Avivagen — Fact Sheet (April 2013)

2 slides from Avivagen's fact sheet, April 2013

Slide 1: Investment Highlights
TMX | LISTED ON INVESTMENT HIGHLIGHTS e Focus on multi-billion dollar companion animal and food animal markets e A potential replacement to antibiotics where antibiotics are getting banned © Oximunol™ canine launched in U.S.; further companion animal products coming in 2013 ® Strong IP to back up pr
Slide 2: The Value of Our Products
THE VALUE OF OUR PRODUCTS OxC-beta, the active ingredient in Oximunol™, QWANZNCIASI NUT By Nel ale) Cato is a highly concentrated version of oxidized derivatives of carotenoids that are found naturally © A fully oxidized form of beta-carotene, which has been discovered to and extensively in the plan